Astec Lifesciences Ltd
₹726.50
+5.15 (0.71%)
Fri, 23 Oct 2026, 02:07 pm
Process Industries
Chemicals: Agricultural
24.5KAstec Lifesciences Ratios
| Particulars | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 4.47 | 15.92 | 36.30 | 4.93 | 7.85 | 19.38 | 76.77 | 61.70 | 32.61 | 29.50 | 16.48 | 30.12 | 38.22 | 106.03 | 0 | 0 |
| Price to book ratio | 0 | 0.89 | 0.80 | 0.51 | 0.29 | 0.60 | 2.11 | 3.21 | 8.53 | 6.70 | 5.20 | 3.17 | 6.34 | 8.66 | 6.46 | 5.64 | 5.64 |
| Price to sales ratio | 0 | 0.53 | 0.71 | 0.44 | 0.17 | 0.33 | 1.08 | 1.66 | 4 | 3.15 | 2.45 | 1.50 | 3.53 | 5.08 | 4.32 | 4.54 | 3.48 |
| Price to cash flow ratio | 0 | 8.73 | 5.57 | 10.58 | 2.83 | 6.67 | 47.32 | 0 | 159.69 | 20.87 | 322.19 | 5.03 | 0 | 228.64 | 46.20 | 0 | 0 |
| Enterprise value | 0 | 94.1Cr | 119Cr | 106Cr | 93.86Cr | 146Cr | 373Cr | 501Cr | 1301Cr | 1261Cr | 1229Cr | 880Cr | 2145Cr | 3712Cr | 3050Cr | 2574Cr | 1875Cr |
| Enterprise value to EBITDA ratio | 0 | 3.69 | 7.55 | 6.27 | 3.26 | 3.95 | 6.84 | 14.54 | 20.72 | 20.02 | 15.60 | 10.18 | 19.04 | 23.88 | 38.77 | 0 | 0 |
| Debt to equity ratio | 1.36 | 0.40 | 0.45 | 0.73 | 0.66 | 0.73 | 0.73 | 1.08 | 0.92 | 0.73 | 0.87 | 0.40 | 0.61 | 0.70 | 0.81 | 1.34 | 2.36 |
| Return on equity % | 0 | 21.11 | 5.17 | 1.40 | 5.83 | 7.91 | 11.88 | 3.92 | 15 | 22.69 | 19.21 | 21.16 | 23.41 | 25.47 | 6.26 | -11.89 | -44.61 |
Astec Lifesciences Ltd Ratios
The Astec Lifesciences Ltd Ratios page provides a complete fundamental analysis of Astec Lifesciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Astec Lifesciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.
Astec Lifesciences Ltd (NSE: ASTEC, BSE: 533138) is currently trading at ₹726.50, with a market capitalization of ₹1606.81Cr. As a major player in the Process industries sector and Chemicals: agricultural industry, Astec Lifesciences Ltd remains a key stock for fundamental analysis using Astec Lifesciences Ltd Ratios.
Astec Lifesciences Ltd Ratios: Valuation Overview
Price to Earnings Ratio (P/E)
The Astec Lifesciences Ltd P/E ratio currently stands at 0, making it one of the most tracked metrics in Astec Lifesciences Ltd Ratios.
Historically, the Astec Lifesciences Ltd P/E ratio has shown strong fluctuations:
- 2025: 0
- 2024: 0
- 2023: 106.03
- 2022: 38.22
- 2021: 30.12
The decline in Astec Lifesciences Ltd P/E ratio suggests improving earnings relative to stock price.
Price to Book Ratio (P/B)
The Astec Lifesciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 5.64.
Historical P/B trend:
- 2025: 5.64
- 2024: 5.64
- 2023: 6.46
- 2022: 8.66
Astec Lifesciences Ltd is trading at a premium to its book value, indicating strong market confidence.
Price to Sales Ratio (P/S)
The Astec Lifesciences Ltd P/S ratio currently stands at 3.48, an important part of Astec Lifesciences Ltd Ratios for revenue valuation.
Historical P/S ratio:
- 2025: 3.48
- 2024: 4.54
- 2023: 4.32
- 2022: 5.08
A stable or declining Astec Lifesciences Ltd P/S ratio indicates cautious market sentiment.
Astec Lifesciences Ltd Price to Cash Flow Ratio (P/CF)
The Astec Lifesciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 0.
Historical Astec Lifesciences Ltd Price to Cash Flow Ratio:
- 2025: 0
- 2024: 0
- 2023: 46.20
- 2022: 228.64
- 2021: 0
The declining Astec Lifesciences Ltd Price to Cash Flow Ratio suggests improving cash flow strength.
Astec Lifesciences Ltd Enterprise Value Ratios
Enterprise Value (EV)
The Astec Lifesciences Ltd EV currently stands at ₹1875Cr, representing the total company valuation including debt.
Historical EV trend:
- 2025: 1875Cr
- 2024: 2574Cr
- 2023: 3050Cr
- 2022: 3712Cr
Astec Lifesciences Ltd enterprise value consolidation suggests stable valuation.
EV/EBITDA Ratio
The Astec Lifesciences Ltd EV/EBITDA ratio is currently 0, a key metric in Astec Lifesciences Ltd Ratios to assess valuation relative to earnings.
Historical EV/EBITDA:
- 2025: 0
- 2024: 0
- 2023: 38.77
- 2022: 23.88
Stable Astec Lifesciences Ltd EV/EBITDA indicates balanced valuation.
Astec Lifesciences Ltd Financial Strength Ratios
Debt to Equity Ratio (D/E)
The Astec Lifesciences Ltd D/E ratio is currently 2.36, reflecting leverage and financial stability.
Historical D/E:
- 2025: 2.36
- 2024: 1.34
- 2023: 0.81
- 2022: 0.70
Higher D/E ratio indicates rising financial risk.
Return on Equity (ROE %)
The Astec Lifesciences Ltd ROE currently stands at -44.61%, showing profitability and capital efficiency.
Historical ROE:
- 2025: -44.61
- 2024: -11.89
- 2023: 6.26
- 2022: 25.47
Declining ROE indicates pressure on profitability.
Astec Lifesciences Ltd Ratios Analysis Summary
The Astec Lifesciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Astec Lifesciences Ltd stock is undervalued, fairly valued, or overvalued.
Tracking Astec Lifesciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.
